Guidelines for the management of hemophilia.

Hemophilia is a rare disorder that is complex to diagnose and to manage. These evidence-based guidelines offer practical recommendations on the diagnosis and general management of hemophilia, as well as the management of complications including musculoskeletal issues, inhibitors, and transfusion-transmitted infections. By compiling these guidelines, the World Federation of Hemophilia aims to assist healthcare providers seeking to initiate and/or maintain hemophilia care programs, encourage practice harmonization around the world and, where recommendations lack adequate evidence, stimulate appropriate studies.

The dental management of adult patients with haemophilia and other congenital bleeding disorders.

The management of adult dental patients with congenital bleeding disorders has caused a considerable number of problems to the dental profession. There is a need to simplify the process and identify what can be safely carried out on a 'shared care' basis in General Dental Practice or the Community Dental Service. Particular problems are discussed with special reference to those requiring hospital care. The Scottish Oral Health Group for Medically Compromised Patients has developed this clinical guidance in conjunction with the Scottish Haemophilia Directors. It is important that dental care is easily available for this group of patients, especially those living at some distance from the regional centres. The aim is to simplify planning dental care for this group of patients and remove a number of myths concerning their management. The hospital departments, both medical and dental, must be available for advice and to arrange for treatment that is inappropriate outside a specialist hospital.

The high pH therapy for cancer tests on mice and humans.

Mass spectrographic and isotope studies have shown that potassium, rubidium, and especially cesium are most efficiently taken up by cancer cells. This uptake was enhanced by Vitamins A and C as well as salts of zinc and selenium. The quantity of cesium taken up was sufficient to raise the cell to the 8 pH range. Where cell mitosis ceases and the life of the cell is short. Tests on mice fed cesium and rubidium showed marked shrinkage in the tumor masses within 2 weeks. In addition, the mice showed none of the side effects of cancer. Tests have been carried out on over 30 humans. In each case the tumor masses disappeared. Also all pains and effects associated with cancer disappeared within 12 to 36 hr; the more chemotherapy and morphine the patient had taken, the longer the withdrawal period. Studies of the food intake in areas where the incidences of cancer are very low showed that it met the requirements for the high pH therapy.

The response of colon carcinoma in mice to cesium, zinc and vitamin A.

Predetermined amounts of cesium chloride or carbonate, zinc gluconate and vitamin A were used together to alter growth of colon carcinoma (C38) implants in BDF1 mice. Data show that the use of these compounds in a treatment protocol is responsible for repression of tumor growth.

The effects of rubidium on mammary tumour growth in C57 blk/6J mice.

A high pH therapy for cancer arrived at theoretically was tested in mice by feeding them rubidium carbonate. Tumours were transplanted in the abdomen of mice and allowed to grow for 8 days. The mice were then divided into two groups. The control group was continued on conventional mouse chow. The test group, in addition to the mouse chow, was force-fed 1.11 mg of rubidium carbonate dissolved in distilled water. At the end of 13 more days the tumours in the controls had grown to a large size so all the mice were sacrificed. The tumours were then removed and weighed. The tumours in the test animals weighed essentially one eleventh of those in the controls. In addition the test animals were showing no adverse effects from the cancers. The probability that this marked difference in tumour size could have come about by chance is exceedingly small.

Further studies on skull growth in achondroplasic (cn) mice.

The morphology of the basioccipital, basisphenoid and mandibular bones in achondroplasic (cn/cn) mice was compared with that of normal siblings. The two bones of the cranial base were markedly reduced in length but not in width. The percentage reduction in the basisphenoid was twice that in the basioccipital bone and of the same magnitude as that previously observed in the long bones of the limbs. This difference may arise because the basisphenoid, like the long bones, grows in length from two cartilaginous growth sites while the basioccipital grows from one cartilaginous and one periosteal site. The mandible of the cn/cn mice was also reduced in size, although to a lesser extent than were the cranial bones and without the ensuing disproportion. The scale of the mandibular changes suggests that they are largely attributable to regulatory responses to the shortened cranium. The finding that the condylar cartilage of the cn/cn mice is reduced in thickness indicates, however, that the cn gene may have a direct effect on condylar chondrocytes.